Robin Zoň

3.2k total citations
71 papers, 2.1k citations indexed

About

Robin Zoň is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Robin Zoň has authored 71 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 22 papers in Public Health, Environmental and Occupational Health and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robin Zoň's work include Economic and Financial Impacts of Cancer (14 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Ethics in Clinical Research (10 papers). Robin Zoň is often cited by papers focused on Economic and Financial Impacts of Cancer (14 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Ethics in Clinical Research (10 papers). Robin Zoň collaborates with scholars based in United States, Australia and Canada. Robin Zoň's co-authors include Richard L. Schilsky, Cynthia S. Johnson, Gary H. Lyman, Susan Scarvalone, Denise R. Aberle, Audrey F. Saftlas, Susan D. Reed, Sandra Millon‐Underwood, Greg Yothers and Pamela Ganschow and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Robin Zoň

70 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robin Zoň United States	25	931	517	375	333	293	71	2.1k
Carolien H. Smorenburg Netherlands	27	1.6k 1.7×	541 1.0×	551 1.5×	222 0.7×	291 1.0×	99	3.0k
Julien Péron France	28	1.0k 1.1×	453 0.9×	240 0.6×	151 0.5×	363 1.2×	121	2.1k
Carolyn J. Presley United States	24	1.2k 1.3×	566 1.1×	181 0.5×	275 0.8×	162 0.6×	150	2.0k
Johanneke E.A. Portielje Netherlands	33	1.7k 1.8×	571 1.1×	745 2.0×	249 0.7×	430 1.5×	144	3.4k
Reda Wilson United States	20	985 1.1×	460 0.9×	375 1.0×	265 0.8×	258 0.9×	42	2.3k
R. Otter Netherlands	26	1.2k 1.3×	506 1.0×	511 1.4×	327 1.0×	452 1.5×	58	2.7k
Laura Giordano Italy	31	982 1.1×	873 1.7×	230 0.6×	215 0.6×	305 1.0×	165	3.3k
Margaret Kemeny United States	23	1.4k 1.5×	494 1.0×	862 2.3×	295 0.9×	364 1.2×	71	2.7k
Lauren P. Wallner United States	28	656 0.7×	430 0.8×	283 0.8×	225 0.7×	268 0.9×	130	2.0k
Ulrich Wedding Germany	30	1.5k 1.6×	808 1.6×	240 0.6×	722 2.2×	351 1.2×	156	3.5k

Countries citing papers authored by Robin Zoň

Since Specialization

Citations

This map shows the geographic impact of Robin Zoň's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Zoň with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Zoň more than expected).

Fields of papers citing papers by Robin Zoň

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Zoň. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Zoň. The network helps show where Robin Zoň may publish in the future.

Co-authorship network of co-authors of Robin Zoň

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Zoň. A scholar is included among the top collaborators of Robin Zoň based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Zoň. Robin Zoň is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hart, Nicolas H., Larissa Nekhlyudov, Thomas J. Smith, et al.. (2024). Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations. JCO Oncology Practice. 20(9). 1160–1172. 9 indexed citations

Tevaarwerk, Amyé, et al.. (2022). The Future of Telemedicine in Oncology. Journal of the National Comprehensive Cancer Network. 20(5.5). 1–5. 4 indexed citations

Zoň, Robin, Erin B. Kennedy, Kerin B. Adelson, et al.. (2021). Telehealth in Oncology: ASCO Standards and Practice Recommendations. JCO Oncology Practice. 17(9). 546–564. 92 indexed citations

Durm, Greg Andrew, Salma K. Jabbour, Sandra K. Althouse, et al.. (2020). A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179. Cancer. 126(19). 4353–4361. 116 indexed citations

Durm, Greg Andrew, Sandra K. Althouse, Salma K. Jabbour, et al.. (2019). P1.18-05 ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy. Journal of Thoracic Oncology. 14(10). S627–S627. 1 indexed citations

Durm, Greg Andrew, Sandra K. Althouse, Alia Sadiq, et al.. (2018). OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC. Journal of Thoracic Oncology. 13(10). S321–S321. 6 indexed citations

Greven, Kathryn M., L. Douglas Case, Lawrence R. Nycum, et al.. (2015). Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106. The Journal of Community and Supportive Oncology. 13(3). 87–94. 4 indexed citations

Jalal, Shadia I., Nasser H. Hanna, Robin Zoň, et al.. (2014). Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies. American Journal of Clinical Oncology. 40(4). 329–335. 2 indexed citations

Mina, Lida A., et al.. (2013). A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109. Investigational New Drugs. 31(5). 1307–1310. 22 indexed citations

10.

Hahn, Noah M., Walter M. Stadler, Robin Zoň, et al.. (2011). Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75. Journal of Clinical Oncology. 29(12). 1525–1530. 147 indexed citations

11.

Loprinzi, Charles L., Ernie Balcueva, Heshan Liu, et al.. (2011). A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Pilocarpine for Vaginal Dryness: North Central Cancer Treatment Group Study N04CA. PubMed. 9(3). 105–112. 9 indexed citations

12.

Greven, Kathryn M., L. D. Case, Lawrence R. Nycum, et al.. (2011). Does L-arginine/Korean ginseng/gingko biloba/damiana-based supplement improve the sexual function and quality of life of female cancer survivors: A randomized trial.. Journal of Clinical Oncology. 29(15_suppl). 9016–9016. 2 indexed citations

13.

Barton, Debra L., Philip J. Atherton, Brent A. Bauer, et al.. (2011). The Use of Valeriana officinalis (Valerian) in Improving Sleep in Patients Who Are Undergoing Treatment for Cancer: A Phase III Randomized, Placebo-Controlled, Double-Blind Study (NCCTG Trial, N01C5). PubMed. 9(1). 24–31. 53 indexed citations

14.

Allegra, Carmen J., Denise R. Aberle, Pamela Ganschow, et al.. (2010). National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. JNCI Journal of the National Cancer Institute. 102(3). 161–169. 278 indexed citations

15.

Allegra, Carmen J., Denise R. Aberle, Pamela Ganschow, et al.. (2009). NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS).. PubMed. 26(2). 1–27. 61 indexed citations

16.

Mina, Lida A., Ian E. Krop, Robin Zoň, et al.. (2009). A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen. Investigational New Drugs. 27(6). 565–570. 24 indexed citations

17.

Hahn, Noah M., Robin Zoň, Menggang Yu, et al.. (2009). A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Annals of Oncology. 20(12). 1971–1976. 14 indexed citations

18.

Miller, KD, Pierluigi Porcu, Rafat Ansari, et al.. (2002). Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. Annals of Oncology. 13(10). 1612–1615. 6 indexed citations

19.

Zoň, Robin, J. McClean, Rafat Ansari, et al.. (2001). Altretamine for the Treatment of Metastatic Renal Cell Carcinoma – A Hoosier Oncology Group Trial. Investigational New Drugs. 19(3). 229–231. 1 indexed citations

20.

Zoň, Robin, Craig R. Nichols, & L H Einhorn. (1998). Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels.. Journal of Clinical Oncology. 16(4). 1294–1297. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact